Nucleome Therapeutics raises oversubscribed £37.5 million Series A financing to decode the dark matter of the human genome and deliver first-in-class precision medicines

October 19, 2022

Stay up to date

Get the latest on cutting edge developments from our enterprises straight to your inbox